↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Seaport Entertainment Group$SEG · filed: grew revenue 18.3% in FY2025 to $130MOld boatNext year $118M–$169M sealedCheck ▾Close ▴
What Seaport Entertainment Group filed
Grew revenue 18.3% in FY2025 to $130 million, operating margin -90.6% against a 7.0% median for miscellaneous amusement & recreation, equity 70.2% of assets. Every figure links to the filing it came from on Seaport Entertainment Group’s card. Old boat: three warning signs.
What the house said in advance
Revenue for the fiscal year after 2025-12-31 between $118M and $169M, an 80% range sealed on 27 Sept 2026 · receipt #6562a9 · graded in public by the revenue in Seaport Entertainment Group’s next annual report.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
Two sub-**$100M** biotech IPOs filed as Kailera priced flat, testing whether venture-backed life sciences can access public markets again at half the 2021 valuations.
$500M
market cap biotechs attempting public listings before the summer…
$100M
in gross proceeds
$16
per share
$101M
and trading flat in its debut session
Seaport Therapeutics and Hemab filed S-1 registration statements with the SEC within hours of each other, joining a narrow queue of sub-$500M market cap biotechs attempting public listings before the summer lull. Seaport, a neuroscience platform spun out of Karuna Therapeutics assets, is targeting $75M to $100M in gross proceeds. Hemab, a rare bleeding disorder specialist with a Phase III hemophilia A asset, filed for a similar range. Both companies are working with syndicates anchored by mid-tier banks—Seaport with Jefferies and Leerink, Hemab with Cowen and SVB Securities.
The filings arrive as Kailera Therapeutics priced its own IPO at $16 per share, raising $101M and trading flat in its debut session. Kailera's performance—neither a pop nor a crater—suggests institutional allocators are willing to underwrite clinical-stage stories again, but only at disciplined entry points. Seaport's lead program, SPN-830, is a TAAR1 agonist in Phase II for major depressive disorder, a crowded indication with half a dozen competitors. Hemab's palovarotene targets heterotopic ossification in hemophilia A patients, a narrow label with $200M peak sales estimates from sell-side models. Neither company has disclosed existing institutional ownership beyond founding venture syndicates.
This matters because the biotech IPO window has been functionally closed since mid-2022, with only nine venture-backed biotech IPOs pricing in 2023 and six in the first half of 2024, down from 79 in 2021. Family offices and crossover funds that bought into late-stage private rounds at $400M to $600M pre-money valuations are now staring at extension rounds or down-round public listings. Seaport and Hemab are testing whether the market will absorb $75M to $100M offerings for single-asset platforms with 18 to 24 months of cash runway post-IPO. If both price, it signals that the venture-to-public bridge is reopening for companies willing to accept $300M to $400M post-money valuations, roughly half the 2021 benchmarks. If either pulls its filing, the window likely stays shut until after the Fed's September meeting.
Operators should watch three things: whether Seaport and Hemab price within 45 days, whether their opening-day trading shows institutional accumulation or retail churn, and whether a third or fourth filing follows in the next 30 days. A cluster of three or more IPOs in a six-week span historically marks a durable reopening. Allocators need to track whether crossover funds that sat out the past 18 months are participating in these syndicates or staying on the sidelines. The tell will be in the amended S-1 filings, typically published 10 to 14 days before pricing, which list cornerstone investors.
Kailera's $16 price and flat debut suggest the market is willing to clear, but not reward. That is enough for biotechs sitting on 12 months of cash to roll the dice.
Branded by POPS4 · proof in 60 seconds
For the principal
Track amended S-1s in 10 days for cornerstone investor lists; institutional participation signals durable window, retail-only syndicates signal false start.
For the operator
If both IPOs price within 45 days, small-cap biotech allocations become viable again; flat debuts acceptable, 20% pops or withdrawals reset timeline to Q4.
For the house
Huang Goodman opens 2.5% position in Kailera post-lockup expiry (180 days); Seaport and Hemab on watchlist pending syndicate composition and Phase II data drops.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.
